Loading stock data…
BIO
$257.86+1.31 (+0.51%)
After Hours$257.99+0.13 (+0.05%)· Last close May 4
Bio-Rad Laboratories, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bio-Rad Laboratories, Inc. in the Healthcare sector is trading at $257.86. The stock is currently 25% below its 52-week high of $343.12, remaining 11.8% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why BIO maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$257.86
Potential Upside
74.6%
Whystock Fair Value$450.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Hold
Mean target$286.25+11.0%
Range$275.00 – $300.00
Fundamentals
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.12B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.80
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.28%
Volume
Today's trading volume
570,029
Recent News
How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions
Biocon’s fair value estimate has been trimmed slightly from ₹420.74 to about ₹416.53, signalling a modest reset in how analysts are sizing up the stock today. That shift lines up with a broader, more cautious tone in recent research on life sciences companies, where execution risk, revenue trajectories and the market’s willingness to pay up after guidance disappointments are under close review. As you read on, you will see how these moving pieces shape the evolving Biocon narrative and what...
Bio-Rad (BIO) Q2 2025 Earnings Call Transcript
Today, we will review the second quarter 2025 financial results and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; Jon Jonathan DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer.
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Bio-Rad (BIO) Q1 2026 Earnings Transcript
Ruben Argueta: Thank you, Regina. My name is Ruben Argueta, Bio-Rad's new Head of IR. Today, we will review the financial results for the first quarter ended March 31, 2026, and provide an update on key business trends for Bio-Rad.
Bio-Rad Laboratories, Inc. Q1 2026 Earnings Call Summary
Moby summary of Bio-Rad Laboratories, Inc.'s Q1 2026 earnings call